tumorinduced

Tumorinduced is an adjectival expression used in medical literature to describe effects, symptoms, or syndromes caused by a neoplasm. It covers both local consequences of tumor growth and remote systemic disturbances produced by tumor biology, including paraneoplastic phenomena that are not a direct result of tumor mass. In clinical practice, tumorinduced manifestations often reflect abnormal production of hormones, growth factors, or cytokines by tumor cells, immune cross-reactivity, or metabolic disruption linked to malignancy.

Mechanisms underlying tumorinduced phenomena include ectopic hormone or peptide secretion, cytokine release, and metabolic or electrolyte disturbances. These effects can occur with various tumor types and may present before a tumor is detected, after treatment, or during progression. They may require multidisciplinary management, combining oncologic treatment with endocrinologic, metabolic, or neurologic care.

Common tumorinduced conditions cited in the literature include non-islet cell tumor hypoglycemia, caused by ectopic IGF-2 production; tumor-induced osteomalacia, due to excess fibroblast growth factor 23 causing phosphate wasting; humoral hypercalcemia of malignancy, often from PTH-related peptide; and a range of paraneoplastic neurologic and dermatologic syndromes. These entities illustrate how tumors can influence distant physiology beyond local tumor burden.

Diagnosis typically involves clinical assessment, targeted laboratory testing for specific biomarkers, and imaging to identify and characterize the underlying tumor. Management centers on treating the tumor itself when possible, supplemented by supportive care to address metabolic, immunologic, or neurologic complications. The term “tumorinduced” serves as a descriptive category in oncology and endocrinology.